Erasca, Inc.
ERAS
Classement en actions
#3566
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Prix de l'action
$13.68
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$4.78B
Changement (1 jour)
2.13%
Changement (1 an)
455.89%
Pays
US
Échange Erasca, Inc. (ERAS)
Catégorie
Healthcare
Historique du rendement du dividende pour Erasca, Inc. (ERAS)
Le rendement du dividende (TTM) de Erasca, Inc. (symbole boursier : ERAS) au 2023-12-31 est : 0.00%
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Erasca, Inc. (ERAS) de 2019 à 2026
Rendement du dividende à la fin de chaque année (TTM)
| Année | Rendement du dividende | Changez |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
| Entreprise | Rendement du dividende | Pays |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
